India · Delayed Price · Currency is INR Dr. Lal PathLabs Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw double-digit revenue and EBITDA growth, driven by volume gains, network expansion, and strong B2C performance. Outlook for FY 2027 is early to mid-teens revenue growth with stable margins, supported by continued investment and broad-based regional momentum.
-
Revenue grew 10.6% YoY in Q3 FY26, with strong EBITDA margin of 27.2% and robust cash reserves. Preventive health packages and digital innovation drove growth, while a one-time Labour Code cost impacted PAT. Management expects stable margins and organic growth ahead.
-
Revenue grew 10.7% YoY in Q2 FY26 with strong profitability and a PAT increase of 16.4%. Investments in digital, AI, and high-end diagnostics, along with disciplined network expansion, are driving growth. Interim dividend and a 1:1 bonus issue were announced.
-
Q1 FY26 saw 11.3% revenue growth and 24.3% profit after tax increase, driven by higher volumes, favorable test mix, and expansion in bundled and specialized testing. Guidance for 11–12% revenue growth is maintained, with margins expected to remain strong.
Fiscal Year 2025
-
Revenue grew 10.5% in FY 2025, outpacing industry, with strong expansion in labs and digital infrastructure. FY 2026 guidance targets 11-12% revenue growth and ~27% EBITDA margin, as investments continue in new geographies and advanced diagnostics.
-
Q3 FY25 saw 10.7% revenue growth, strong Delhi NCR performance, and Swasthfit packages up 27.2% YoY. Expansion continues in Tier 2/3/4 markets, with a focus on volume growth, digital infrastructure, and high-end diagnostics. Net cash stands at INR 1,123 crore.
-
Revenue and profit grew 9.8% and 18.1% year-over-year in Q2 FY25, driven by network expansion, bundled test packages, and strong West region performance. Margins improved, with no price hikes, and guidance remains for double-digit growth and stable margins.
-
Q1 FY 2025 saw 11.3% revenue growth, strong profitability, and robust expansion in Tier 3/4 towns. Suburban Diagnostics integration and digital investments are progressing, with specialized and wellness portfolios driving growth. Cash reserves support dividends, acquisitions, and infrastructure.